NASDAQ:TRILTrillium Therapeutics Stock Price, Forecast & News

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TRIL shares have increased by 51.6% and is now trading at $7.87. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trillium Therapeutics.

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Trillium Therapeutics.

Trillium Therapeutics Inc (NASDAQ:TRIL) released its earnings results on Friday, May, 15th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.14. View Trillium Therapeutics' earnings history.

3 analysts have issued 1 year target prices for Trillium Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Trillium Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 27.1% from the stock's current price. View analysts' price targets for Trillium Therapeutics.

News articles about TRIL stock have trended negative on Sunday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trillium Therapeutics earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View the latest news about Trillium Therapeutics.

Trillium Therapeutics saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 5,850,000 shares, a decrease of 5.2% from the May 31st total of 6,170,000 shares. Based on an average trading volume of 2,460,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 8.0% of the company's shares are short sold. View Trillium Therapeutics' Current Options Chain.

Some companies that are related to Trillium Therapeutics include Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), Opko Health (OPK), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Xencor (XNCR), Principia Biopharma (PRNB) and Prestige Consumer Healthcare (PBH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Opko Health (OPK), TG Therapeutics (TGTX), Karyopharm Therapeutics (KPTI) and VBI Vaccines (VBIV).

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRIL stock can currently be purchased for approximately $7.87.

Trillium Therapeutics has a market capitalization of $656.67 million and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]